<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000552.v2.p1" parentStudy="phs000552.v2.p1" createDate="2014-04-07" modDate="2014-04-07">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Co-Principal Investigator</td><td>Rameen Beroukhim, MD, PhD</td><td>Dana-Farber Cancer Institute, Boston, MA 02215, USA</td></tr>
		<tr><td>Co-Principal Investigator</td><td>Ian F. Dunn, MD</td><td>Brigham and Women&#39;s Hospital, Boston MA 02115, USA</td></tr>
		<tr><td>Co-Principal Investigator</td><td>William C. Hahn, MD, PhD</td><td>Dana-Farber Cancer Institute, Boston, MA 02215, USA</td></tr>
		<tr><td>Co-Principal Investigator</td><td>Peleg M. Horowitz, MD</td><td>Brigham and Women&#39;s Hospital, Boston MA 02115, USA</td></tr>
		<tr><td>Co-Principal Investigator</td><td>Priscilla K. Brastianos, MD</td><td>Dana-Farber Cancer Institute, Boston, MA 02215, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Genomic Characterization of Meningiomas</StudyNameEntrez>
	<StudyNameReportPage>Genomic Characterization of Meningiomas</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Meningiomas are the most common primary brain tumor in the US. Although the tumor suppressor gene NF2 is disrupted in approximately half of meningiomas, the complete spectrum of genetic changes in meningiomas remains poorly understood, particularly in the large subset of tumors without NF2 alterations. Therefore we performed whole-genome sequencing from 11 Grade I meningioma tumor-normal pairs and whole-exome sequencing from an additional 6 tumor-normal pairs to identify somatic mutations, insertions-deletions, copy-number alterations and rearrangements. We validated our results by performing focused sequencing across 48 additional meningiomas.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>- Histopathologic purity of &#8805;90%</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="23334667"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Meningioma"/>
	</Diseases>
	<Attributions>
		<Header title="Co-Principal Investigator">
			<AttName>Rameen Beroukhim, MD, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, Boston, MA 02215, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigator">
			<AttName>Ian F. Dunn, MD</AttName>
			<Institution>Brigham and Women&#39;s Hospital, Boston MA 02115, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigator">
			<AttName>William C. Hahn, MD, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, Boston, MA 02215, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigator">
			<AttName>Peleg M. Horowitz, MD</AttName>
			<Institution>Brigham and Women&#39;s Hospital, Boston MA 02115, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigator">
			<AttName>Priscilla K. Brastianos, MD</AttName>
			<Institution>Dana-Farber Cancer Institute, Boston, MA 02215, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Sandro Santagata, MD, PhD</AttName>
			<Institution>Brigham and Women&#39;s Hospital, Boston MA 02115, USA</Institution>
		</Header>
		<Header title="Other Investigator">
			<AttName>Gad Getz, PhD</AttName>
			<Institution>Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA</Institution>
		</Header>
		<Header title="Other Investigator">
			<AttName>Matthew D. Ducar</AttName>
			<Institution>Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02215, USA</Institution>
		</Header>
		<Header title="Other Investigator">
			<AttName>Keith L. Ligon, MD, PhD</AttName>
			<Institution>Brigham and Women&#39;s Hospital, Boston MA 02115, USA</Institution>
		</Header>
		<Header title="Other Investigator">
			<AttName>David N. Louis, MD</AttName>
			<Institution>Massachusetts General Hospital, Boston, MA 02114, USA</Institution>
		</Header>
		<Header title="Other Investigator">
			<AttName>Anat O. Stemmer-Rachamimov, MD</AttName>
			<Institution>Massachusetts General Hospital, Boston, MA 02114, USA</Institution>
		</Header>
		<Header title="Other Investigator">
			<AttName>Aaron McKenna</AttName>
			<Institution>Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>BSF Grant # 7059402</AttName>
			<Institution>Brain Science Foundation, Brigham and Women&#39;s Hospital, Boston MA 02115, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-BDBC-NPU-MDS" longName="Disease-Specific (Brain Disorders and Brain Cancer, NPU, MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000552.v2.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000552.v2.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000552.v2.p1" FileName="eNCI_0145_DUC_8.22.2012.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (Brain Disorders and Brain Cancer, NPU, MDS)</ConsentName>
        <ConsentAbbrev>DS-BDBC-NPU-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Brain Disorders and Brain Cancer.
Use of the data is limited to not-for-profit organizations.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>
  <Documents>
    <Document phd="phd004138.1" type="consent-form" createDate="2012-12-27" modDate="2012-12-27">
      <OrigName>ConsentFormBWHNeuropathology.pdf</OrigName>
      <DisplayName>Partners HealthCare System Research Consent Form</DisplayName>
      <Description>Partners HealthCare System Research Consent Form</Description>
      <displayStatus>stage-1</displayStatus>
      <xmlStatus>preview</xmlStatus>
    </Document>
  </Documents>


<Analyses>
	<Analysis pha="3577" genomeBuild="" snpBuild="" analysisType="">
		<Description>This dataset contains data from a case set of 65 pairs of meningiomas and normal blood DNA, sequenced on Illumina HiSeq 2000. Of the 47 Grade I cases, 11 where sequenced by whole-genome methods, six were sequenced by whole-exome capture, and 30 were sequenced by OncoPanel, a custom target sequencing approach covering 645 cancer-related genes. An additional 15 Grade II and 3 Grade III tumor-normal pairs were sequenced by OncoPanel.</Description>
		<Method>Somatic mutation analysis</Method>
		<Comment></Comment>
	</Analysis>
</Analyses>

</Study>

</Studies>

</GaPExchange>
